TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Stepped Primary Care Smoking Cessation Intervention Based on an Evidence Based Clinical Practice Guideline (ISTAPS Project)
Brief Summary: Primary care centers can play a very important role in helping people to stop smoking. There is a large body of research on the effectiveness of specific interventions especially addressed to people who want to stop smoking. In addition to that, there are no studies with a large sample of individuals included that tested the complete range of interventions recommended nowadays for helping people in the different smoking cessation stages of change and with different degrees of physical and psychological dependence, especially including motivational interviewing in those not interested in cessation in the very next weeks. This study will test a complex intervention that at first classifies smokers in stages and after that treats every smoker according to what stage he/she is in at the moment, his/her degree of dependence and his/her own characteristics.


Options:
A: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Care for Smoking Cessation in PTSD patients | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Integrated Care for Smoking Cessation in PTSD patients; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Arm 2
C: Intervention Type: BEHAVIORAL; Name: Advice; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nicotine Gum and Patch; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A
D: Arm Label: Implementation of intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Training in smoking cessation counseling | Arm Label: No implementation of the intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training in smoking cessation counseling; Assigned to Arm(s): Implementation of intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension.


Options:
A: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): ambrisentan, sugar pill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension.


Options:
A: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Ambrisentan
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure
Brief Summary: This is a two-center, randomised, single-blind (physician), prospective, controlled study to assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure (CHF).

The hypotheses are:

* Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose improves exercise capacity as measured by peak VO2.
* IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Saline
C: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
D: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo (saline)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure
Brief Summary: This is a two-center, randomised, single-blind (physician), prospective, controlled study to assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure (CHF).

The hypotheses are:

* Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose improves exercise capacity as measured by peak VO2.
* IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.


Options:
A: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ferinject | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject, Placebo
B: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo
C: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure
Brief Summary: This is a two-center, randomised, single-blind (physician), prospective, controlled study to assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure (CHF).

The hypotheses are:

* Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose improves exercise capacity as measured by peak VO2.
* IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
C: Arm Label: Ferric carboxymaltose; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Normal saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): Ferric carboxymaltose | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Ferric carboxymaltose, Placebo
D: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evidence Based Amputee Rehabilitation (EBAR) Program
Brief Summary: The purpose of this study is to determine if an evidence based exercise intervention improves the functional mobility of diabetic amputees (single lower leg amputation) who have already completed standard rehabilitation and prosthetic training.


Options:
A: Arm Label: Error-augmentation training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-augmentation gait training | Arm Label: Error-correction training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-correction gait training | Arm Label: Supervised waking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised walking | Intervention Type: BEHAVIORAL; Name: Error-augmentation gait training; Assigned to Arm(s): Error-augmentation training | Intervention Type: BEHAVIORAL; Name: Error-correction gait training; Assigned to Arm(s): Error-correction training | Intervention Type: BEHAVIORAL; Name: Supervised walking; Assigned to Arm(s): Supervised waking
B: Arm Label: Left transtibial; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Right transtibial; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Left transfemoral; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Right transfemoral; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Provider; Type: N/A; Interventions: Device: KinetiGait | Intervention Type: DEVICE; Name: KinetiGait; Assigned to Arm(s): Left transfemoral, Left transtibial, Provider, Right transfemoral, Right transtibial
C: Arm Label: Exercise, activity, and self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Walking Program, Behavioral: Health Self-Management Support | Arm Label: Home and phone visit; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Walking Program; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Health Self-Management Support; Assigned to Arm(s): Exercise, activity, and self-management
D: Arm Label: EBAR Program; Type: EXPERIMENTAL; Interventions: Other: EBAR Program | Arm Label: Wait List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EBAR Program; Assigned to Arm(s): EBAR Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05
Brief Summary: The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination. Most patients receive 2 or 3 lines of chemotherapy. The aim of this randomized trial is to evaluate the potential benefit of a bitherapy with 5-fluorouracil (5-FU) and oxaliplatin as first line chemotherapy compared with a sequential chemotherapy with 5-FU alone as first line chemotherapy followed by the combination of 5-FU with oxaliplatin in case of progressive disease, in terms of progression-free survival and overall survival in patients with advanced colorectal cancer.


Options:
A: Arm Label: Regorafenib (Stivarga, BAY73-4506)+BSC; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib (Stivarga, BAY73-4506), Other: Best Supportive Care (BSC) | Arm Label: Placebo+BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Regorafenib (Stivarga, BAY73-4506); Assigned to Arm(s): Regorafenib (Stivarga, BAY73-4506)+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo+BSC, Regorafenib (Stivarga, BAY73-4506)+BSC
B: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
C: Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): N/A
D: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this trial is to determine whether a conservative or a liberal blood transfusion strategy is better for patients with a heart attack and a low blood count.


Options:
A: Intervention Type: DRUG; Name: Red blood cell transfusion; Assigned to Arm(s): N/A
B: Arm Label: Treatment group; Type: EXPERIMENTAL; Interventions: Other: Ultrafiltration of residual blood | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Ultrafiltration of residual blood | Intervention Type: OTHER; Name: Ultrafiltration of residual blood; Assigned to Arm(s): Control, Treatment group
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Intervention Type: BIOLOGICAL; Name: Red Blood Cell Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Packed Red Blood Cell Transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Packed Red Blood Cell Transfusion | Intervention Type: PROCEDURE; Name: Packed Red Blood Cell Transfusion; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this trial is to determine whether a conservative or a liberal blood transfusion strategy is better for patients with a heart attack and a low blood count.


Options:
A: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Packed Red Blood Cell Transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Packed Red Blood Cell Transfusion | Intervention Type: PROCEDURE; Name: Packed Red Blood Cell Transfusion; Assigned to Arm(s): 1, 2
C: Arm Label: Blood transfusion triggers of 24% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 24% | Arm Label: Blood transfusion triggers of 28% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 28% | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 24%; Assigned to Arm(s): Blood transfusion triggers of 24% hematocrit value | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 28%; Assigned to Arm(s): Blood transfusion triggers of 28% hematocrit value
D: Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Liberal transfusion strategy | Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Behavioral: Restrictive transfusion strategy | Intervention Type: BEHAVIORAL; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal | Intervention Type: BEHAVIORAL; Name: Restrictive transfusion strategy; Assigned to Arm(s): Restrictive

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this trial is to determine whether a conservative or a liberal blood transfusion strategy is better for patients with a heart attack and a low blood count.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose | Arm Label: EPOFE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Erythropoietin | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): EPOFE, FE | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): EPOFE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Haemoglobin (<6.0 mmol/l); Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Haemoglobin (< normal range); Type: EXPERIMENTAL; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Haemoglobin (< normal range), Haemoglobin (<6.0 mmol/l)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Packed Red Blood Cell Transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Packed Red Blood Cell Transfusion | Intervention Type: PROCEDURE; Name: Packed Red Blood Cell Transfusion; Assigned to Arm(s): 1, 2
D: Arm Label: Liberal blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Arm Label: Restrictive blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Liberal blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Restrictive blood transfusion

Answer: C